127 related articles for article (PubMed ID: 16627982)
21. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms.
Nakayama K; Nakayama N; Kurman RJ; Cope L; Pohl G; Samuels Y; Velculescu VE; Wang TL; Shih IeM
Cancer Biol Ther; 2006 Jul; 5(7):779-85. PubMed ID: 16721043
[TBL] [Abstract][Full Text] [Related]
22. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
23. The presence of multiple regions of homozygous deletion at the CSMD1 locus in oral squamous cell carcinoma question the role of CSMD1 in head and neck carcinogenesis.
Toomes C; Jackson A; Maguire K; Wood J; Gollin S; Ishwad C; Paterson I; Prime S; Parkinson K; Bell S; Woods G; Markham A; Oliver R; Woodward R; Sloan P; Dixon M; Read A; Thakker N
Genes Chromosomes Cancer; 2003 Jun; 37(2):132-40. PubMed ID: 12696061
[TBL] [Abstract][Full Text] [Related]
24. Potential role of the inactivated X chromosome in ovarian epithelial tumor development.
Cheng PC; Gosewehr JA; Kim TM; Velicescu M; Wan M; Zheng J; Felix JC; Cofer KF; Luo P; Biela BH; Godorov G; Dubeau L
J Natl Cancer Inst; 1996 Apr; 88(8):510-8. PubMed ID: 8606379
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression.
Nilforoushan N; Moatamed NA
Ann Diagn Pathol; 2020 Oct; 48():151582. PubMed ID: 32866902
[TBL] [Abstract][Full Text] [Related]
26. Allele loss from large regions of chromosome 17 is common only in certain histological subtypes of ovarian carcinomas.
Papp J; Csokay B; Bosze P; Zalay Z; Toth J; Ponder B; Olah E
Br J Cancer; 1996 Nov; 74(10):1592-7. PubMed ID: 8932340
[TBL] [Abstract][Full Text] [Related]
27. Mitogen-activated protein kinase kinase 4/c-Jun NH2-terminal kinase kinase 1 protein expression is subject to translational regulation in prostate cancer cell lines.
Robinson VL; Shalhav O; Otto K; Kawai T; Gorospe M; Rinker-Schaeffer CW
Mol Cancer Res; 2008 Mar; 6(3):501-8. PubMed ID: 18337456
[TBL] [Abstract][Full Text] [Related]
28. A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus.
Jacobs IJ; Smith SA; Wiseman RW; Futreal PA; Harrington T; Osborne RJ; Leech V; Molyneux A; Berchuck A; Ponder BA
Cancer Res; 1993 Mar; 53(6):1218-21. PubMed ID: 8095178
[TBL] [Abstract][Full Text] [Related]
29. Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer.
Cvetkovic D; Pisarcik D; Lee C; Hamilton TC; Abdollahi A
Gynecol Oncol; 2004 Dec; 95(3):449-55. PubMed ID: 15581945
[TBL] [Abstract][Full Text] [Related]
30. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
[TBL] [Abstract][Full Text] [Related]
31. Amplicon profiles in ovarian serous carcinomas.
Nakayama K; Nakayama N; Jinawath N; Salani R; Kurman RJ; Shih IeM; Wang TL
Int J Cancer; 2007 Jun; 120(12):2613-7. PubMed ID: 17351921
[TBL] [Abstract][Full Text] [Related]
32. Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization.
Hauptmann S; Denkert C; Koch I; Petersen S; Schlüns K; Reles A; Dietel M; Petersen I
Hum Pathol; 2002 Jun; 33(6):632-41. PubMed ID: 12152163
[TBL] [Abstract][Full Text] [Related]
33. CDKN2A gene inactivation in epithelial sporadic ovarian cancer.
Niederacher D; Yan HY; An HX; Bender HG; Beckmann MW
Br J Cancer; 1999 Aug; 80(12):1920-6. PubMed ID: 10471040
[TBL] [Abstract][Full Text] [Related]
34. Chromosome 6 abnormalities in ovarian surface epithelial tumors of borderline malignancy suggest a genetic continuum in the progression model of ovarian neoplasms.
Tibiletti MG; Bernasconi B; Furlan D; Bressan P; Cerutti R; Facco C; Franchi M; Riva C; Cinquetti R; Capella C; Taramelli R
Clin Cancer Res; 2001 Nov; 7(11):3404-9. PubMed ID: 11705855
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of a region on chromosome 1p in ovarian serous carcinoma that is frequently deleted in uterine papillary serous carcinoma.
Herzog TJ; Kowalski LD; Liu H; Arlt M; Swisher E
Gynecol Oncol; 2001 Jul; 82(1):139-42. PubMed ID: 11426975
[TBL] [Abstract][Full Text] [Related]
36. [Expression P53 protein and chromosome aberrations in benign tumors and ovarian carcinoma].
Kamiński K; Putowski L; Oleszczuk J
Ginekol Pol; 2003 Sep; 74(9):741-5. PubMed ID: 14674118
[TBL] [Abstract][Full Text] [Related]
37. Deletion mapping of two potential chromosome 14 tumor suppressor gene loci in ovarian carcinoma.
Bandera CA; Takahashi H; Behbakht K; Liu PC; LiVolsi VA; Benjamin I; Morgan MA; King SA; Rubin SC; Boyd J
Cancer Res; 1997 Feb; 57(3):513-5. PubMed ID: 9012483
[TBL] [Abstract][Full Text] [Related]
38. Identification of allelic losses in benign, borderline, and invasive epithelial ovarian tumors and correlation with clinical outcome.
Saretzki G; Hoffmann U; Röhlke P; Psille R; Gaigal T; Keller G; Höfler H; Löning T; Petersen I; Dietel M
Cancer; 1997 Oct; 80(7):1241-9. PubMed ID: 9317174
[TBL] [Abstract][Full Text] [Related]
39. [Study on the expression of the gene deleted in colorectal carcinoma in ovarian carcinoma].
Li PL; Liu MM; Ni J
Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):207-9. PubMed ID: 12885365
[TBL] [Abstract][Full Text] [Related]
40. MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course.
Xin W; Yun KJ; Ricci F; Zahurak M; Qiu W; Su GH; Yeo CJ; Hruban RH; Kern SE; Iacobuzio-Donahue CA
Clin Cancer Res; 2004 Dec; 10(24):8516-20. PubMed ID: 15623633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
